[HTML][HTML] Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
[HTML][HTML] SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies
Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …
and are especially important in high-risk individuals where vaccination is not an option …
[HTML][HTML] Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19
MJ Levin, A Ustianowski, S De Wit… - … England Journal of …, 2022 - Mass Medical Soc
Background The monoclonal-antibody combination AZD7442 is composed of tixagevimab
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …
[HTML][HTML] Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
D Planas, N Saunders, P Maes, F Guivel-Benhassine… - Nature, 2022 - nature.com
Abstract The SARS-CoV-2 Omicron variant was first identified in November 2021 in
Botswana and South Africa,–. It has since spread to many countries and is expected to …
Botswana and South Africa,–. It has since spread to many countries and is expected to …
[HTML][HTML] FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation
C Junqueira, Â Crespo, S Ranjbar, LB De Lacerda… - Nature, 2022 - nature.com
SARS-CoV-2 can cause acute respiratory distress and death in some patients. Although
severe COVID-19 is linked to substantial inflammation, how SARS-CoV-2 triggers …
severe COVID-19 is linked to substantial inflammation, how SARS-CoV-2 triggers …
[HTML][HTML] Serum neutralization of SARS-CoV-2 Omicron sublineages BA. 1 and BA. 2 in patients receiving monoclonal antibodies
The severe acute respiratory syndrome coronavirus 2 Omicron BA. 1 sublineage has been
supplanted in many countries by the BA. 2 sublineage. BA. 2 differs from BA. 1 by about 21 …
supplanted in many countries by the BA. 2 sublineage. BA. 2 differs from BA. 1 by about 21 …
[HTML][HTML] Resistance of Omicron subvariants BA. 2.75. 2, BA. 4.6, and BQ. 1.1 to neutralizing antibodies
Convergent evolution of SARS-CoV-2 Omicron BA. 2, BA. 4, and BA. 5 lineages has led to
the emergence of several new subvariants, including BA. 2.75. 2, BA. 4.6. and BQ. 1.1. The …
the emergence of several new subvariants, including BA. 2.75. 2, BA. 4.6. and BQ. 1.1. The …
Emergence of SARS-CoV-2 Omicron (B. 1.1. 529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic
Since the appearance in the late of December 2019, SARS-CoV-2 is rapidly evolving and
mutating continuously, giving rise to various variants with variable degrees of infectivity and …
mutating continuously, giving rise to various variants with variable degrees of infectivity and …
[HTML][HTML] Inflammasome activation in infected macrophages drives COVID-19 pathology
Severe COVID-19 is characterized by persistent lung inflammation, inflammatory cytokine
production, viral RNA and a sustained interferon (IFN) response, all of which are …
production, viral RNA and a sustained interferon (IFN) response, all of which are …
[HTML][HTML] Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost
The Omicron variant of SARS-CoV-2 infected many vaccinated and convalescent
individuals,–. Despite the reduced protection from infection, individuals who received three …
individuals,–. Despite the reduced protection from infection, individuals who received three …